Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840250 | 0.90 | HTR6 (0.67) | HTR6HTR2CHTR2BALDH1A1THRB | |
| SCHEMBL3842279 | 0.86 | HTR6 (0.45) | HTR6HTR2CHTR2BALDH1A1MAPK1 | |
| SCHEMBL3840272 | 0.84 | HTR2C (0.55) | HTR6HTR2CHTR2B | |
| SCHEMBL3839924 | 0.83 | HTR6 (0.64) | HTR6HTR2CHTR2BALDH1A1THRB | |
| SCHEMBL3092592 | 0.81 | FNTA (0.53) | HTR2CHTR2BMAPTMAPK1NPSR1 | |
| SCHEMBL3840194 | 0.80 | HTR2C (0.59) | HTR6HTR2CHTR2B | |
| SCHEMBL3841615 | 0.77 | HTR2C (0.53) | HTR6HTR2CHTR2B | |
| SCHEMBL4865743 | 0.76 | HTR6 (0.47) | HTR6HTR2CCYP3A4HTR2B | |
| SCHEMBL13989700 | 0.74 | HTR2C (0.55) | HTR6HTR2CHTR2B | |
| SCHEMBL3840397 | 0.74 | HTR6 (0.61) | HTR6HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | claimed |
| JP-2008524274-A | — | — | 2008-07-10 | — | — | JP | claimed |
| CN-101124210-A | Tetrahydronaphthalene and indane derivatives and their use | ROCHE PALO ALTO LLC (CH) | 2008-02-13 | — | — | CN | claimed |
| EP-1831189-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | claimed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | claimed |
| WO-2006066745-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | HTR6 1638/4885HTR2C 1508/4885CYP3A4 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.